CTOs on the Move


 
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.imv-inc.com
  • 130 Eileen Stubbs Ave
    Dartmouth, NS CAN B3B 2C4
  • Phone: 902.492.1819

Executives

Name Title Contact Details

Funding

IMV raised $29.5M on 03/11/2019
IMV raised $25.1M on 05/18/2020

Similar Companies

NGM Biopharmaceuticals

NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio`s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.

Sentien Biotechnologies Inc

Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel approaches to cell therapy. Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.

Lacerta Therapeutics

Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases

Y-mAbs Therapeutics

YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.

NICO

NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.